Navigation Links
PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
Date:8/18/2011

ANNAPOLIS, Md., Aug. 18, 2011 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) take necessary steps to improve drug reimbursement under the Hospital Outpatient Perspective Payment System (OPPS).

At last week's Advisory Panel on Ambulatory Payment Classification (APC) Groups meeting, PPTA testified that the continued failure by CMS to remove hospitals that purchase drugs under the 340B program from its OPPS reimbursement rate-setting calculation may create difficulties for patients in their attempt to access some drugs and biologicals because including 340B sales in the calculation artificially lowers the payment level.

The agency sets the payment level for separately payable drugs and biologicals with non-pass-through status based on their ratio of cost to average sales price (ASP).  The cost totals are based on claims data from all hospitals, including 340B hospitals, but the ASP data excludes 340B sales. Setting the rate in this manner does not reflect the actual cost of acquiring and preparing drugs and biologicals for any hospitals, because 340B sales prices are well below ASP.  For those hospitals not receiving the 340B discount on drug purchases, their reimbursement level may become too low to be able to continue offering certain drugs and biologicals to their patients for administration.

Based on this calculation, CMS has proposed for calendar year 2012 to set the payment level of separately payable non-pass-through drugs and biologicals, which include most plasma protein therapies, at ASP plus 4 percent. The current payment level is ASP plus 5 percent.  PPTA believes, however, that this payment rate should be no less than ASP plus 6 percent to help ensure that hospital outpatient departments remain a viable option for beneficiaries to receive therapies such as alpha-1 proteinase inhibitor, blood clotting factors and intravenous immune globulin (IVIG). "PPTA has long advocated for parity between the statutory physician office rate of ASP plus 6 and the OPPS rate," said Julie Birkofer, senior vice president, North America, PPTA. "This inequality between sites of service has been problematic in the past for patient access to plasma protein therapies."

PPTA testimony also underscored the staggering growth of 340B hospital sites in recent years.  The number of 340B hospital sites has more than doubled in three years – from 2,213 enrolled in the fourth quarter of 2008 to 4,427 enrolled today.  This growth of the 340B program will exacerbate the flawed nature of the agency's rate setting calculation, according to PPTA.  

Although PPTA advocates for removing 340B sales from the CMS rate setting calculation, it cautioned against establishing two payment rates – one for 340B hospitals and one for non-340B hospitals.  "Reducing Medicare payments to 340B hospitals [through a separate payment rate] for separately paid drugs would undermine the purpose of the 340B program to reach more eligible patients and provide more comprehensive services," said Birkofer.

Maintaining an appropriate reimbursement level is an important step in ensuring access to plasma protein therapies, which are highly complex biologics, for Medicare beneficiaries suffering from rare, chronic and genetic diseases and disorders including primary immunodeficiency diseases, hemophilia and other bleeding disorders and alpha-1 antitrypsin deficiency, a genetic lung disease. Plasma protein therapies refer to plasma-derived and recombinant blood clotting factors, as well as alpha-1 proteinase inhibitor and immune globulins.

PPTA testified as part of a panel of stakeholders advocating to improve drug reimbursement under OPPS and providing input on the 2012 OPPS Proposed Rule. The group comprised representatives from the Association of Community Cancer Centers, Biotechnology Industry Association (BIO), and the Alliance of Dedicated Cancer Centers.  The stakeholders also urged the APC Advisory Panel to recommend that CMS reallocate more money than the proposed $215 million in pharmacy overhead costs from packaged drugs to separately payable drugs by redistributing the same percentage of costs from the coded and uncoded packaged drug pools.  PPTA was deeply disappointed that the Panel failed to make of the stakeholders' proposed recommendations to the agency at the conclusion of the meeting.

PPTA appreciates the opportunity to testify with stakeholders at the APC Advisory Panel meeting and make recommendations to CMS that will help ensure access to plasma protein therapies for rare disease patients.

For more information about PPTA, please visit www.pptaglobal.org or contact Kym Kilbourne at 443-458-4682 or 443-995-2101.

The Plasma Protein Therapeutics Association (PPTA) represents the world's leading manufacturers of plasma-derived and recombinant biological therapies, collectively known as plasma protein therapies. These critical therapies are infused or injected by more than 1 million people worldwide to treat a variety of rare, life threatening diseases and serious medical conditions. PPTA members produce in excess of 80 percent of the plasma protein therapies used in the United States today. PPTA is a global trade association that administers international, voluntary standards programs to help ensure the highest quality and safety of plasma protein therapies and the plasma collected to manufacture them. Additionally, PPTA works in partnership with the patient community and consumer advocates to help ensure continued access to lifesaving plasma protein therapies.

Contact:Kym H. Kilbourne

 

 

443-995-2102

 

 

kkilbourne@pptaglobal.org

 
     


'/>"/>
SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
2. Clean Power Development, LLC Urges Sustainable, Community-Centric Approach to Biomass Energy
3. Tax Specialty Firm McGuire Sponsel Urges Qualifying Biotech Companies to Apply for New Qualifying Therapeutic Discovery Project Credit Soon
4. DuPont Science Leader Urges U.S. House Committee to Continue Federal Investment in Transformative, Clean Energy Technologies
5. VirtualHealth Technologies Will Change Its Name to VHGI Holdings, Inc. and Surges Forward Into Broader Market
6. Regional Biotech Association Urges Support for Biosimilars Bill in Congress
7. TechNet Urges Swift U.S. Senate Approval of FCC Nominees Julius Genachowski and Robert McDowell
8. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
9. FCSO Selects Burgess as Exclusive Pricing Solution for New Medicare Contract
10. Beyond Turbidity: Selecting Appropriate Technology for in Situ Monitoring and Control of Complex Particle and Droplet Systems
11. Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The ... reach USD 92.9 billion by 2025, according to ... Pharmaceutical industry has been adaptive of the function ... early as 2002. Among the services outsourced, clinical ... For instance, Johnson & Johnson was the first ...
(Date:1/19/2017)... , Jan. 18, 2017 Acupath Laboratories, Inc., ... the formation of an Executive Committee that will guide ... John Cucci , a 15-year veteran ... Director of Business Development to Chief Sales Officer ... Cucci served in senior sales leadership roles at several ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
Breaking Biology Technology:
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... Colo. , Jan. 5, 2017  SomaLogic ... the "Digital Life Alliance" established by iCarbonX, the ... 2015 to build a "Global Digital Health Ecosystem ... on a combination of individual,s biological, behavioral and ... the agreement between the companies, SomaLogic will provide ...
Breaking Biology News(10 mins):